BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 19:25:14 | |||
| 92 EUR | +0.49% |
|
92.05 | +0.05% |
| 05-29 | BioMérieux: head injury test cleared by the FDA | CF |
| 05-28 | BioMérieux: FDA clearance for Vidas TBI test | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.9B 4.22B 329B | Sales 2025 * | 4.19B 4.54B 354B | Capitalization | 10.82B 11.71B 913B |
|---|---|---|---|---|---|
| Net income 2024 * | 465M 504M 39.26B | Net income 2025 * | 527M 571M 44.49B | EV / Sales 2024 * | 2.72 x |
| Net cash position 2024 * | 217M 235M 18.36B | Net cash position 2025 * | 400M 433M 33.77B | EV / Sales 2025 * | 2.48 x |
| P/E ratio 2024 * |
23.8
x | P/E ratio 2025 * |
21
x | Employees | 13,696 |
| Yield 2024 * |
0.97% | Yield 2025 * |
1.13% | Free-Float | 36.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | +0.49% | ||
| 1 week | -3.36% | ||
| Current month | -5.30% | ||
| 1 month | -5.15% | ||
| 3 months | -6.94% | ||
| 6 months | -5.95% | ||
| Current year | -8.55% |
1 week
91.00
96.65
1 month
91.00100.10
Current year
91.00108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 31/10/16 |
| Chairman | 50 | 15/04/04 | |
| Director of Finance/CFO | 47 | 28/02/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 14/09/06 | |
| Director/Board Member | 63 | 31/12/04 | |
| Chairman | 50 | 15/04/04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 15 M€ | -3.67% | ||
| 0.26% | 1,056 M€ | +4.41% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/24 | 92 | +0.49% | 90 708 |
| 11/06/24 | 91.55 | -0.44% | 80,542 |
| 10/06/24 | 91.95 | -1.97% | 101,780 |
| 07/06/24 | 93.8 | -1.78% | 95,457 |
| 06/06/24 | 95.5 | +0.32% | 75,849 |
Real-time Euronext Paris, June 12, 2024 at 04:35 pm
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
03/09/2024
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
91.55
EUR
Average target price
113.5
EUR
Spread / Average Target
+23.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.55% | 11.6B | |
| -2.58% | 8.11B | |
| +7.73% | 5.67B | |
| +30.30% | 5.62B | |
| -15.77% | 3.89B | |
| +12.42% | 2.68B | |
| -61.09% | 2.58B | |
| -5.50% | 2.26B | |
| +26.54% | 2.03B | |
| -9.25% | 1.82B |
- Stock Market
- Equities
- BIM Stock